News | Computed Tomography (CT) | March 27, 2018

Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study

Company also updates European launch for Sapien 3 Ultra System to late 2018

Edwards Completes Enrollment in PARTNER 3 Low-Risk CT Sub-Study
Valve Thrombosis Comparison

March 27, 2018 — Edwards Lifesciences Corp. announced that enrollment is complete in the computed tomography (CT) imaging sub-study within the PARTNER 3 trial of the Sapien 3 valve. This randomized sub-study is examining leaflet mobility of both the Sapien 3 valve and surgical heart valves in low-risk patients undergoing valve replacement for the treatment of severe aortic stenosis.

Enrollment in the PARTNER 3 main study of the Sapien 3 valve in low-risk patients was already complete. As previously indicated, Edwards continues to anticipate that data from the PARTNER 3 trial will be presented at the American College of Cardiology (ACC) 2019 annual meeting, and expects to receive U.S. Food and Drug Administration (FDA) approval for the indication late that year.

In addition, Edwards is studying the Sapien 3 Ultra System as part of a single-arm multi-center trial of up to 30 intermediate-risk patients. These data will be utilized to supplement the European regulatory filing for the Sapien 3 Ultra System. Edwards now expects that the European launch of the Sapien 3 Ultra system will occur later in 2018. This updated timing for the European launch does not change the company's sales guidance for 2018, and Edwards continues to expect the U.S. introduction of this system in late 2018.

For more information: www.edwards.com

 

Related Content

Amazon Comprehend Medical Brings Medical Language Processing to Healthcare
News | Artificial Intelligence | February 15, 2019
Amazon recently announced Amazon Comprehend Medical, a new HIPAA-eligible machine learning service that allows...
Siemens Healthineers Demonstrates Artificial Intelligence, Healthcare Digitalization at HIMSS19
News | Artificial Intelligence | February 13, 2019
February 13, 2019 — At the 2019 Healthcare Information and Management Systems Society (HIMSS) global conference and e
Canon Adds Radiation Therapy Package to Aquilion Prime, Lightning CT Systems
News | Computed Tomography (CT) | February 11, 2019
In the patient-centric world of radiation oncology, it is critical that computed tomography (CT) simulation is...
New Appropriate Use Criteria Outlined for Multimodality Imaging of Nonvalvular Heart Disease
News | Cardiac Imaging | February 11, 2019
The American College of Cardiology (ACC), along with nine other cardiology professional societies, recently published a...
Fujifilm Launches Latest Synapse 3D Version at HIMSS 2019

The new Intravoxel Incoherent Motion (IVIM) MR application in Synapse 3D

Technology | Advanced Visualization | February 08, 2019
Fujifilm Medical Systems U.S.A. will debut the latest version of its Synapse 3D solution at the Healthcare Information...
Korean National Training Center Installs Carestream OnSight 3D Extremity System
News | Computed Tomography (CT) | February 07, 2019
Jincheon National Training Center in Jincheon, South Korea, installed a Carestream OnSight 3D Extremity System at its...
Canon Medical Debuts Alphenix 4-D CT at RSNA 2018
Technology | Angiography | February 06, 2019
Canon Medical Systems USA Inc. recently introduced a new angiography configuration featuring its Alphenix Sky + C-arm...
Canon Medical Systems Launches Alphenix Interventional Imaging Line
Technology | Angiography | February 04, 2019
Canon Medical Systems USA recently introduced its next generation of interventional systems – the Alphenix platform....
Study Assesses Risk of MRI Exams for Patients With Tattoos
News | Magnetic Resonance Imaging (MRI) | February 01, 2019
A new European study concluded that magnetic resonance imaging (MRI) exams pose little risk for people with tattoos,...
Stereotactic Radiotherapy Improves Long-Term Survival in Stage-IV Cancers
News | Stereotactic Body Radiation Therapy (SBRT) | January 31, 2019
The first report from a phase II, multi-center clinical trial indicates stereotactic radiation can extend long-term...